Department of Hepatobiliary Surgery, Institute of Advanced Surgical Technology and Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Hepatobiliary Surgery, Institute of Advanced Surgical Technology and Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Division of Surgical Oncology, The Ohio State University, Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
HPB (Oxford). 2020 Feb;22(2):215-223. doi: 10.1016/j.hpb.2019.05.020. Epub 2019 Jun 21.
To define recurrence patterns and time course, as well as risk factors associated with recurrence following curative resection of pNETs.
Patients who underwent curative-intent resection for pNET between 1997 and 2016 were identified from the US Neuroendocrine Tumor Study Group. Data on baseline and tumor-specific characteristics, overall survival (OS), timing and first-site of recurrence, predictors and recurrence management were analyzed.
Among 1020 patients, 154 (15.1%) patients developed recurrence. Among patients who experienced recurrence, 76 (49.4%) had liver-only recurrence, while 35 (22.7%) had pancreas-only recurrence. The proportion of liver-only recurrence increased from 54.3% within one-year after surgery to 61.5% from four-to-six years after surgery; whereas the proportion of pancreas-only recurrence decreased from 26.1% to 7.7% over these time periods. While liver-only recurrence was associated with tumor characteristics, pancreas-only recurrence was only associated with surgical margin status. Patients undergoing curative resection of recurrence had comparable OS with patients who had no recurrence (median OS, pancreas-only recurrence, 133.9 months; liver-only recurrence, not attained; no recurrence, 143.0 months, p = 0.499) CONCLUSIONS: Different recurrence patterns and timing course, as well as risk factors suggest biological heterogeneity of pNET recurrence. A personalized approach to postoperative surveillance and treatment of recurrence disease should be considered.
明确胰腺神经内分泌肿瘤(pNET)根治性切除术后的复发模式和时间进程,以及与复发相关的危险因素。
从美国神经内分泌肿瘤研究组中确定了 1997 年至 2016 年间接受根治性手术治疗的 pNET 患者。分析了患者的基线和肿瘤特异性特征、总生存(OS)、复发时间和首发部位、预测因素和复发管理数据。
在 1020 例患者中,有 154 例(15.1%)患者发生了复发。在复发的患者中,有 76 例(49.4%)为肝脏单部位复发,35 例(22.7%)为胰腺单部位复发。肝脏单部位复发的比例从术后 1 年内的 54.3%增加到术后 4 至 6 年的 61.5%;而胰腺单部位复发的比例从这一时期的 26.1%下降到 7.7%。肝脏单部位复发与肿瘤特征有关,而胰腺单部位复发仅与手术切缘状态有关。接受根治性切除复发灶的患者与无复发患者的 OS 相当(胰腺单部位复发的中位 OS 为 133.9 个月;肝脏单部位复发未达到;无复发为 143.0 个月,p=0.499)。
不同的复发模式和时间进程以及危险因素表明 pNET 复发具有生物学异质性。应考虑采用个性化的术后监测和复发疾病治疗方法。